On December 20, Gelonghui announced that TIANJIN DEV (00882.HK) had approved a share buyback plan at the Board of Directors meeting held on December 20, 2024. Accordingly, starting from December 21, 2024, Tianjin Lisheng Pharmaceutical is authorized to repurchase its ordinary shares through competitive bidding on the Shenzhen Stock Exchange at the current market price for a total amount of no less than RMB 76.5 million and no more than RMB 0.153 billion within a twelve-month period.

The Board of Directors of Tianjin Lisheng Pharmaceutical proposed to adopt a stock incentive plan to grant no more than 7,210,000 restricted shares to 150 target incentive recipients, including senior and middle management and key employees, subject to approval by the shareholders at the shareholders' meeting. This represents 2.80% of the total issued capital of Tianjin Lisheng Pharmaceutical as of the date of this announcement.